Pars Capital Partners, LLC is a premier, pure-play independent investment banking services advisory and investment firm dedicated exclusively to the global clinical trial infrastructure and pharmaceutical outsourcing markets.
Our mission is to bridge the gap between complex life-science operations and sophisticated institutional grade corporate finance.
The clinical trial outsourcing space is governed by strict, unforgiving regulatory frameworks, such as FDA/EMA guidance, current Good Manufacturing Practices (cGMP), and Good Clinical Practices (GCP). A single operational deviation can destroy years of drug development.
Pars Capital approaches corporate transactions with that exact same philosophy. Our transactional DNA is anchored in the Managing Partner's historical FINRA and SEC broker registration, forged at world-class institutional broker-dealers including Morgan Stanley, Merrill Lynch Bank of America, and BrokerBank Securities.
We bring institutional data integrity, strict confidentiality, and regulatory precision to a middle market historically vulnerable to unvetted buyers, loose disclosures, and leaks that damage enterprise value.
Unlike generalist business brokers, regional finders, or traditional mid-market investment banks, Pars Capital operates with a single, uncompromised focus on the clinical research outsourcing ecosystem. We eliminate the operational learning curve entirely. We understand capacity utilization, cleanroom classifications, therapeutic modalities, and clinical trial phase transitions out of the box, speaking the exact scientific and manufacturing language of our clients.
The clinical trial outsourcing space is governed by strict, unforgiving regulatory frameworks. A single operational deviation can destroy years of drug development. Pars Capital approaches corporate transactions with that exact same philosophy, bringing institutional data integrity, strict confidentiality, and regulatory precision to a middle market historically vulnerable to unvetted buyers, loose disclosures, and leaks that damage enterprise value.
A firm's advisory execution is only as strong as its distribution network. Pars Capital has systematically mapped both the CRO and CDMO sub-sectors from the ground up. We enter every market mandate backed by:
A private conversation regarding your long-term operational goals, timelines, and succession strategy.
Execution of a strict mutual NDA prior to any secure business data exchange occurring.
Crafting a compelling institutional investment narrative backed by quantitative sub-sector metrics.
Selective, highly confidential engagement of deeply vetted, mandated buyers.
Meticulously managing data rooms, structures, and due diligence to shield your legacy and maximize close value.
Pars Capital Partners coordinates all due diligence, financial underwriting, and auditing through isolated, institutional-grade virtual data rooms.
Knowing your true fair market price is essential for long-term strategic planning, whether you are preparing for an immediate strategic exit or exploring structural growth capital. Pars Capital offers a highly technical, completely confidential assessment of your business based on current market conditions.
All submissions are routed directly to the Managing Partner.